Eli Lilly shares drop
Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed since the drug's launch in late 2023.
Lilly, Mounjaro and Zepbound
AbbVie's CEO hinted his company may be less willing to invest in psychiatry after a costly setback, while Lilly explained ...
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...
Pharmaceutical Technology on MSN7h
Lilly gains US FDA approval for Omvoh to treat Crohn’s diseaseEli Lilly has received approval from the US FDA for Omvoh to treat moderately to severely active Crohn's disease in the adult ...
The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...
Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases ...
JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...
GlobalData on MSN2d
Eli Lilly targets Scorpion Therapeutics to expand reach in oncologyAfter selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the ...
Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.
Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. | For nearly a decade, Eli Lilly has been ...
Stocktwits on MSN1d
Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays BullishEli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback